<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Gilead Sciences Inc. | Company News & Executive Profiles - GILD | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/gilead+sciences+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Gilead Sciences Inc.]]></description>
	<s:counts start="0" returned="10" found="466" />
	<language>en-us</language>
	<item>
		<title><![CDATA[GlaxoSmithKline Seeks to Commercialize Viread in China for Hepatitis B]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175261-glaxosmithkline-seeks-to-commercialize-viread-in-china-for-hepatitis-b%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  GlaxoSmithKline GSK and Gilead Sciences GILD agreed on an Asian marketing plan for their jointly owned treatment for hepatitis B, Viread® tenofovir disoproxil fumarate. GSK will have exclusive rights to commercialize the drug for hepatitis B in China. Gilead will own exclusive rights Hong Kong, Singapore,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 04:11:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GILD,GSK</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences Is in Great Health]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167928-gilead-sciences-is-in-great-health%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  &#8220;Check out Gilead. Profit up 36% from a year ago. Well ahead of expectations at 78 cents [non-GAAP] versus a 67 estimate. The revenues grew 31% from a year ago. Product sales strong, royalties strong, but the stock is down. Only thing I can see, that...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 21 Oct 2009 12:00:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences, Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-354660.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions And our first question comes from the line of Geoff Meacham with JPMorgan. Go ahead. Geoff Meacham &#8211; JPMorgan Hey guys, congrats on the quarter and thanks for taking the question. Question for you, I am trying to reconcile product sales guidance with...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 20 Oct 2009 20:32:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/guidance.html"><![CDATA[Guidance]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Taking Profits from Swine Flu with Tamiflu]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160871-taking-profits-from-swine-flu-with-tamiflu%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  Flu season is approaching quickly and fresh fears over a possible H1N1 epidemic have taken hold.  Hospitals and pharmacies are stocking up on medications to counter such an outbreak, and the most popular drug to treat flu is Tamiflu.  Tamiflu was developed by Gilead...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 10 Sep 2009 09:33:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences: Expect Share Price to Move Up]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159973-gilead-sciences-expect-share-price-to-move-up%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Gilead Sciences GILD is a good bio-technology companies with their strong franchise in HIV, a growing franchise in Hepatitis and potential in cardio-vascular therapies. Many think of Gilead as the provider of Tamiflu, a therapy for influenza. However, Tamiflu is a small part of the story and it has limited...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 04 Sep 2009 02:43:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/hans+wagner.html"><![CDATA[Hans Wagner]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Subpoena Will Have Investors Guessing: What's Wrong With the CVT Acquisition?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003724/gilead-subpoena-will-have-investors-guessing-whats-wrong-with-the-cvt-acquisition/]]></link>
		<description><![CDATA[Gilead's single-sentence announcement that it has received a subpoena regarding Ranexa from the Office of the Inspector General of HHS could be nothing or anything. One thing is for sure, securities class-action lawyers will be watching this very closely, as the subpoena comes just a few months after Gilead acquired...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 17 Aug 2009 12:35:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/subpoena.html"><![CDATA[Subpoena]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[Investor]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+office.html"><![CDATA[Microsoft Office]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/office+suites.html"><![CDATA[Office Suites]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Created "Cocktail Bar for Rats" to Test Anti-Booze Drug]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003690/gilead-created-cocktail-bar-for-rats-to-test-anti-booze-drug/]]></link>
		<description><![CDATA[Gilead has done some entertaining tests of an anti-booze drug in rats. The company introduced rats to sugar water cocktails, and gradually increased the booze content within them. They also set up a rat "bar" -- a special cage  -- where the drinks were served. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 14 Aug 2009 12:56:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/rat.html"><![CDATA[Rat]]></category>
		<category domain="http://resources.bnet.com/topic/cocktail.html"><![CDATA[Cocktail]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/food+%2526+beverage.html"><![CDATA[Food & Beverage]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Axes 139 Jobs in Colorado; CVT Reps Get Culture Shock]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003663/gilead-axes-139-jobs-in-colorado-cvt-reps-get-culture-shock/]]></link>
		<description><![CDATA[Gilead is laying off 66 people as it closes its Colorado offices to consolidate its operations in California. Gilead "hopes to relocate 73 of the 139 staff" that work in Colorado to California. The move should not be a surprise. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 13 Aug 2009 14:15:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/colorado.html"><![CDATA[Colorado]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/recruitment+%2526+selection.html"><![CDATA[Recruitment & Selection]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead to close Colorado offices]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/gilead-colorado-offices/7479/]]></link>
		<description><![CDATA[The biotech has chosen to close the Colorado offices following the $1.4bn (???1bn) acquisition of California-based CV Therapeutics. This created an overlap in expertise that Gilead is resolving by closing the Colorado offices. Gilead hopes to relocate 73 of the 139 staff that work in the Colorado offices. The offices...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 13 Aug 2009 07:01:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/office.html"><![CDATA[office]]></category>
		<category domain="http://resources.bnet.com/topic/colorado.html"><![CDATA[Colorado]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Q2 Mystery: Purchase of Less-Efficient CVT Made It a More Efficient Company]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003314/gilead-q2-mystery-purchase-of-less-efficient-cvt-made-it-a-more-efficient-company/]]></link>
		<description><![CDATA[Gilead continues to astonish: If you remove the transaction and restructuring costs, the company's acquisition of CV Therapeutics has actually made it even more efficient than it was before. That's unexpected because CVT was an incredibly inefficient producer of its own revenues. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 27 Jul 2009 13:55:36 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/restructuring.html"><![CDATA[Restructuring]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
</channel>
</rss>
